Brief: Elicera Therapeutics Q2 Operating Loss Widens To SEK 3.7 Million
Aug 22 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q2 LOSS FOR PERIOD TOTALED SEK -3,667,200 (-1,818,888)
* Q2 OPERATING LOSS TOTALED SEK -3,641,800 (-1,818,751)
* WE BELIEVE THAT WITH OUR EXISTING CASH AND BANK BALANCES,
EU
GRANT AND OTHER GRANTS, WE HAVE FINANCING TO CARRY OUT ALL OUR
PROGRAMS AT FULL SPEED UNTIL FIRST HALF OF 2024
Source text for Eikon: ID:nWkr8Xml4B
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application